Sevelamer for treating hyperphosphatemia in pediatric CKD patients
Rachael Williams
This article has no abstract so we have provided the first paragraph of the full text.
Calcium-containing phosphate binders are the current mainstay of treatment for hyperphosphatemia in children with chronic kidney disease (CKD), but they are associated with an increased risk of vascular calcification. Now, researchers in Germany have found that sevelamer, a calcium-free phosphate binder that has been used widely in the adult hemodialysis population, might also be suitable for treating hyperphosphatemia in the pediatric setting.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
